Michael York Net Worth

The estimated Net Worth of Michael York is at least 51.1 千$ dollars as of 26 January 2023. Mr. York owns over 107,054 units of PhaseBio Pharmaceuticals stock worth over 7,255$ and over the last 6 years he sold PHAS stock worth over 43,892$. In addition, he makes 0$ as Vice President - Corporate Development and Commercial Strategy at PhaseBio Pharmaceuticals.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. York PHAS stock SEC Form 4 insiders trading

Michael has made over 1 trades of the PhaseBio Pharmaceuticals stock since 2023, according to the Form 4 filled with the SEC. Most recently he sold 107,054 units of PHAS stock worth 43,892$ on 26 January 2023.

The largest trade he's ever made was selling 107,054 units of PhaseBio Pharmaceuticals stock on 26 January 2023 worth over 43,892$. On average, Michael trades about 15,293 units every 0 days since 2019. As of 26 January 2023 he still owns at least 103,499 units of PhaseBio Pharmaceuticals stock.

You can see the complete history of Mr. York stock trades at the bottom of the page.

Michael York biography

Michael B. York serves as Vice President - Corporate Development and Commercial Strategy of the Company. Prior to joining our company, Mr. York served as the vice president of global business development and alliance management of Orexigen Therapeutics, Inc. from August 2015 to June 2018. He previously served as a senior advisor for MKO Global Partners, L.P. from January 2015 to August 2015. Mr. York received a B.A. in public administration and economics from San Diego State University and an M.B.A. from the University of Redlands.

How old is Michael York?

Michael York is 55, he's been the Vice President - Corporate Development and Commercial Strategy of PhaseBio Pharmaceuticals since 2018. There are 7 older and 9 younger executives at PhaseBio Pharmaceuticals. The oldest executive at PhaseBio Pharmaceuticals, Inc. is Nancy Hutson, 70, who is the Independent Director.

What's Michael York's mailing address?

Michael's mailing address filed with the SEC is C/O METACRINE, INC., 4225 EXECUTIVE SQUARE, SUITE 600, SAN DIEGO, CA, 92037.

Insiders trading at PhaseBio Pharmaceuticals

Over the last 6 years, insiders at PhaseBio Pharmaceuticals have traded over 361,083$ worth of PhaseBio Pharmaceuticals stock and bought 24,000 units worth 81,960$ . The most active insiders traders include Clay Thorp、Enterprise Associates 13 Lp...、Nancy J Hutson. On average, PhaseBio Pharmaceuticals executives and independent directors trade stock every 52 days with the average trade being worth of 5,138$. The most recent stock trade was executed by Clay Thorp on 19 May 2023, trading 3,750 units of PHAS stock currently worth 263$.

What does PhaseBio Pharmaceuticals do?

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.

Complete history of Mr. York stock trades at PhaseBio Pharmaceuticals、Metacrine

PhaseBio Pharmaceuticals executives and stock owners

PhaseBio Pharmaceuticals executives and other stock owners filed with the SEC include:

• Jonathan Mow,
  Chief Executive Officer, Director
• Jonathan P. Mow,
  Pres, CEO & Director
• John Lee,
  Chief Medical Officer
• John Sharp,
  Chief Financial Officer
• Dr. John S. Lee,
  Chief Medical Officer
• John P. Sharp,
  Chief Financial Officer
• Clay Thorp,
  Co-Founder, Independent Chairman of the Board
• Peter Klein,
  Independent Director
• Nancy Hutson,
  Independent Director
• Richard van den Broek,
  Independent Director
• Caroline Loewy,
  Independent Director
• Edmund Harrigan,
  Independent Director
• Alex Sapir,
  Independent Director
• Michael York,
  Vice President - Corporate Development and Commercial Strategy
• Jim Ballance,
  Vice President - Research and Scientific Affairs
• Susan Arnold,
  Vice President - Preclinical and Chemistry, Manufacturing and Controls
• Kristophe Hanson,
  Vice President - Head of Legal, Corporate Secretary
• Glen Burkhardt,
  Vice President - Human Resources
• Jonathan J. Birchall,
  Chief Commercial Officer
• Glen Burkhardt,
  VP of HR
• Lauren Richardson,
  Global Head of Regulatory Affairs & Quality Assurance
• Kristopher L. Hanson,
  VP, Head of Legal & Corp. Sec.
• Bibhash Mukhopadhyay,
  Director
• David James Ballance,
  VP, Research and Sci. Affairs
• Linda Tufts,
  Director
• William D. Humphries,
  Director
• Jonathan Birchall,
  Chief Commercial Officer
• Enterprise Associates 13 Lp...,